Global Respiratory Diagnostics Market is expected to grow with the CAGR of 7.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-respiratory-diagnostics-market

Global respiratory diagnostics market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global respiratory diagnostics market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition and agreement into the respiratory diagnostics market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in May 2020, Abbott received FDA emergency use authorization for Abbott RealTime SARS-CoV-2 EUA tests, COVID-19 detection test. This approval received by the company has enhanced its product portfolio leading to increased sales which ultimately boosted the company’s revenue.

Abbott is the dominating player in global respiratory diagnostics market. The other key players existing in the respiratory diagnostics market includes GE Healthcare (a subsidiary of GENERAL ELECTRIC COMPANY), Koninklijke Philips N.V., Medtronic, BD, COSMED srl, F. Hoffmann-La Roche Ltd, NIHON KOHDEN CORPORATION, Drägerwerk AG & Co. KGaA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., MGC Diagnostics Corporation, Masimo, bioMérieux SA, Carestream Health, VYAIRE, Seegene Inc., ResMed, SDI Diagnostics among others.

Abbott:

Abbott is headquartered in Illinois, U.S. and was founded in 1888. The company focuses on manufacturing products in diagnostics, medical devices, nutrition and branded generic pharmaceuticals that help people to live healthier lives, full of unlimited possibilities. The company has multiple business segments such as established pharmaceutical products, nutritional products, diagnostic products and medical devices in which diagnostic products is the market focused segment. The company is providing products under categories such as cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicines among which diagnostics is the market focused category. The company is engaged in continuous development of respiratory diagnostics.

For instance,

• In September 2020, Abbott launched Panbio COVID-19 Rapid Test in France for supporting the detection of rapidly rising COVID-19 patients in France. This launch of diagnostic tests by the company has increased its credibility in the market.

The company has wide presence across Asia-Pacific, Europe, Middle East and Africa, North America and South America. The company has various subsidiaries such as Abbott Cardiovascular Systems Inc. (U.S.), Abbott Nutrition Manufacturing Inc. (U.S.), Abbott Laboratories Pacific Ltd. (U.S.), Abbott Resources Inc. (U.S.) and PDD II, LLC (U.S.) among others.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is headquartered in Massachusetts, U.S. and was incorporated in 1960. The company focuses on manufacturing scientific instruments, consumables and chemicals. The company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals among others. The company has multiple business segments such as life science solutions, analytical instruments, specialty diagnostics and laboratory products & services in which life science solutions is the market focused segment. The company is providing products under categories such as life sciences, industrial & applied science, clinical & diagnostics and lab solutions among which life sciences and clinical & diagnostics are the market focused categories. The company is engaged in continuous development of respiratory diagnostics.

For instance,

• In July 2018, Thermo Fisher Scientific Inc. has launched its clinical diagnostic product named as VetMAX MastiType qPCR Kits for the easy and faster diagnosis of the respiratory microbes. This new product launched by the company has increased its product portfolio and demand in the market.

The company has wide presence across Europe, North America, South America, Asia-Pacific and Middle East and Africa. The company also has various subsidiary companies such as Thermo Trace Ltd. (Australia), Thermo Electron Holdings SAS (France), Thermo Informatics Asia Pacific Pty Ltd. (Australia), Thermo Finland Holdings LLC (U.S.) and Kendro Laboratory Products (H.K.) Limited (China) among others.

F. Hoffmann-La Roche Ltd:

F. Hoffmann-La Roche Ltd is headquartered in Basel, Switzerland and was founded in 1896. The company is engaged in development and integration of diagnostic solutions to address healthcare challenges by offering in-vitro diagnostics solutions, covering molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing and laboratory automation and IT and decision support solutions. The company has multiple business segments such as pharmaceuticals and diagnostics in which diagnostics is the market focused segment. The company is providing products under categories such as pharmaceuticals, solutions for diagnostics and products for researchers among which solutions for diagnostics is the market focused category. The company is engaged in continuous development of respiratory diagnostics. The company has initiated many strategic initiatives to expand its market.

For instance,

• In September 2020, F. Hoffmann-La Roche Ltd launched its new SARS-CoV-2 Rapid Antigen Test in the countries which accept the CE marked products. This new diagnostic product launch by the company during the time of COVID-19 has increased its credibility in the market.

The company has wide presence across Europe, North America, Africa, Asia and Oceanic. The company has various subsidiary companies such as Roche Diagnostica Brasil Ltda. (Brazil), Roche Diabetes Care Brasil Ltda. (Brazil), Trophos SA (France), INSTITUT ROCHE SAS (France) and Roche Diagnostics K.K. (Japan) among more.